Quote & Headlines
StockTalk
FACT is defunct.
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
Seth Klarman's Baupost Group Exits Facet BiotechMarket Folly • Thu, Apr 22, 2010
-
Seth Klarman's Baupost Group Wins Big With Facet BiotechMarket Folly • Fri, Mar 19, 2010
-
A Lukewarm IPO, White Knight Spice Up Biotech's Latest DealsThe Burrill Report • Mon, Mar 15, 2010
-
Europe Turnaround Drives Up FuturesoptionMONSTER • Fri, Mar 12, 2010
-
Equities Edge a Little HigherMidnight Trader • Wed, Mar 10, 2010
-
Abbott's Acquisition SpreeZacks Investment Research • Wed, Mar 10, 2010
-
Biotechnology M&As, Wholesale Mix the Markets and ETFsTom Lydon • Wed, Mar 10, 2010
-
Facet Board Pleased with Rejection of Biogen BidThe Burrill Report • Sun, Dec 20, 2009
To learn more about Seeking Alpha Pro, click here.
-
Seth Klarman's Baupost Group Wins Big With Facet BiotechMarket Folly • Fri, Mar 19, 2010
-
Seth Klarman's Baupost Group Starts Activism in Facet Biotech PositionMarket Folly • Thu, Apr 30, 2009
-
First Albany: Still Stuck on FirstTim Hussar • Wed, Feb 21, 2007
-
First Albany: Knee Deep in the RedTim Hussar • Wed, Feb 14, 2007
-
Seth Klarman's Baupost Group Exits Facet BiotechMarket Folly • Thu, Apr 22, 2010
-
A Lukewarm IPO, White Knight Spice Up Biotech's Latest DealsThe Burrill Report • Mon, Mar 15, 2010
-
Europe Turnaround Drives Up FuturesoptionMONSTER • Fri, Mar 12, 2010
-
Equities Edge a Little HigherMidnight Trader • Wed, Mar 10, 2010
-
Abbott's Acquisition SpreeZacks Investment Research • Wed, Mar 10, 2010
-
Biotechnology M&As, Wholesale Mix the Markets and ETFsTom Lydon • Wed, Mar 10, 2010
-
Facet Board Pleased with Rejection of Biogen BidThe Burrill Report • Sun, Dec 20, 2009
-
Immunogen's Busy Month, Part IIOhad Hammer • Wed, Dec 2, 2009
There are no Transcripts on FACT.
There are no News articles on FACT.
Company Description
We are a biotechnology company dedicated to advancing our pipeline of several clinical-stage products and expanding and deriving value from our proprietary next-generation protein engineering platform technologies to improve the clinical performance of protein therapeutics.
We were organized... More
Country: United States